Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q2 2026 Earnings Presentation
9 slides from Adc Therapeutics Sa's earnings presentation, Aug 13, 2026
Slide 1: 2Q 2026 Earnings Call
2Q 2026 Earnings Call August 13, 2026
Slide 2: Agenda
Agenda Ameet Mallik 1 Chief Executive Officer Business Update Mohamed Zaki Clinical Update 2 Chief Medical Officer Pepe Carmona Financial Update 3 Chief Financial Officer 4 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we”or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recom
Slide 4: Key Business Updates
Key Business Updates ▪ 2Q 2026 net product revenues of $18.6 million as compared to $18.1 million in same quarter 2025 Commercial Performance ▪ Increase vs. prior quarter primarily driven by price increase, and reflects strong commercial execution together with normal variability in customer orderin
Slide 5: Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas DLBCL Indolent Lymphomas • 2L+ treatment choice is based largely on achieving a rapid • 2L+ treatment choice is driven by tolerability and QoL as well and durable complete response, within the accessible as rate and durability of overall respo
Slide 6: LOTIS-5: Status and planned next steps
LOTIS-5: Status and planned next steps ▪ Met with U.S. FDA in early August 2026 ▪ Totality of topline data discussed Recent ▪ Final meeting minutes from FDA received milestones ▪ FDA feedback indicated substantial concerns regarding the benefit-risk or verification of clinical benefit observed in th
Slide 7: LOTIS-7: Status and potential next steps
LOTIS-7: Status and potential next steps ▪ Target of ~100 patients completed enrollment at selected 150 µg/kg dose in June 2026 Recent milestones ▪ Full data demonstrating potential best-in-class bispecific combination with a safety profile generally consistent with prior disclosures submitted for p
Slide 8: 2Q 2026 Selected Financial Data
L ON CA 2Q 2026 Selected Financial Data Balance Sheet June 30, 2026 Cash and cash equivalents ($M) 219.1 Statement of Operations 2Q 2026 ($M) 2Q 2025 ($M) YoY % Product Revenues, Net 18.6 18.1 3.0 Total Revenue 19.2 18.8 2.2 Total Operating Expenses 44.7 63.0 -29.1 Adjusted Total Operating Expenses
Slide 9: Thank You
Thank You ® THERAPEUTICS Innovating Science. Inspiring Hope.